ArticleFrontiers in immunology2023

Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant.

Xing-Yu Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.